Rocket Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Rocket Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2015-09-30 | 2015-06-30 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | |||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||
| research and development | 42,658,000 | 35,942,000 | 37,357,000 | 42,315,000 | 46,345,000 | 45,227,000 | 41,744,000 | 46,844,000 | 51,383,000 | 46,371,000 | 50,037,000 | 43,383,000 | 41,356,000 | 30,794,000 | 32,161,000 | 39,975,000 | 24,798,000 | 28,542,000 | 21,657,000 | 16,731,000 | 16,957,000 | 14,829,000 | 13,989,000 | 15,137,000 | 13,065,000 | 10,772,000 | 5,743,000 | -7,558,000 | -3,612,000 | -1,954,000 | |
| general and administrative | 25,020,000 | 28,446,000 | 25,337,000 | 27,109,000 | 27,367,000 | 22,148,000 | 21,535,000 | 18,585,000 | 17,374,000 | 15,823,000 | 19,045,000 | 15,105,000 | 12,854,000 | 11,770,000 | 12,172,000 | 9,671,000 | 9,250,000 | 10,680,000 | 5,730,000 | 6,828,000 | 7,163,000 | 4,336,000 | 4,403,000 | 3,808,000 | 2,268,000 | 4,100,000 | 8,662,000 | -7,011,000 | -1,825,000 | -1,728,000 | |
| restructuring | 3,471,000 | ||||||||||||||||||||||||||||||
| total operating expenses | 71,149,000 | 64,388,000 | 62,694,000 | 69,424,000 | 73,712,000 | 67,375,000 | 63,279,000 | 65,429,000 | 68,757,000 | 62,194,000 | 69,082,000 | 58,488,000 | 54,210,000 | 42,564,000 | 44,333,000 | 49,646,000 | 34,048,000 | 39,222,000 | 27,387,000 | 23,559,000 | 24,120,000 | 19,165,000 | 18,392,000 | 18,945,000 | 15,333,000 | 14,872,000 | 14,405,000 | ||||
| income from operations | -71,149,000 | -64,388,000 | -62,694,000 | -69,424,000 | -73,712,000 | -67,375,000 | -63,279,000 | -65,429,000 | -68,757,000 | -62,194,000 | -69,082,000 | -58,488,000 | -54,210,000 | -42,564,000 | -44,333,000 | -49,646,000 | -34,048,000 | -39,222,000 | -27,387,000 | -23,559,000 | -24,120,000 | -19,165,000 | -18,392,000 | -18,945,000 | -15,333,000 | -14,872,000 | -14,405,000 | -14,569,000 | -5,437,000 | -3,682,000 | |
| yoy | -3.48% | -4.43% | -0.92% | 6.11% | 7.21% | 8.33% | -8.40% | 11.87% | 26.83% | 46.12% | 55.83% | 17.81% | 59.22% | 8.52% | 61.88% | 110.73% | 41.16% | 104.65% | 48.91% | 24.35% | 57.31% | 28.87% | 27.68% | 30.04% | 182.01% | 303.91% | |||||
| qoq | 10.50% | 2.70% | -9.69% | -5.82% | 9.41% | 6.47% | -3.29% | -4.84% | 10.55% | -9.97% | 18.11% | 7.89% | 27.36% | -3.99% | -10.70% | 45.81% | -13.19% | 43.21% | 16.25% | -2.33% | 25.85% | 4.20% | -2.92% | 23.56% | 3.10% | 3.24% | -1.13% | 167.96% | 47.66% | ||
| operating margin % | |||||||||||||||||||||||||||||||
| interest expense | -473,000 | -472,000 | -473,000 | -471,000 | -471,000 | -471,000 | -470,000 | -469,000 | -468,000 | -468,000 | -467,000 | -465,000 | -465,000 | -464,000 | -463,000 | -534,000 | -251,000 | -1,729,000 | -1,967,000 | -1,786,000 | -1,573,000 | -1,466,000 | -1,544,000 | -1,604,000 | -1,176,000 | -1,363,000 | -1,427,000 | -2,349,000 | -192,000 | -564,000 | |
| interest and other income | 483,000 | 1,336,000 | 1,617,000 | 1,327,000 | 2,294,000 | 3,029,000 | 814,000 | 1,720,000 | 846,000 | 1,908,000 | 1,245,000 | 1,353,000 | 669,000 | 623,000 | 429,000 | 979,000 | 1,000,000 | ||||||||||||||
| accretion of discount on investments | 2,220,000 | 2,190,000 | 1,713,750 | 1,849,000 | 2,243,000 | 2,763,000 | -124,000 | 62,000 | 368,000 | 256,000 | 247,000 | ||||||||||||||||||||
| net income | -68,919,000 | -61,334,000 | -60,327,000 | -66,719,000 | -69,646,000 | -62,054,000 | -59,660,000 | -61,899,000 | -65,701,000 | -58,335,000 | -66,723,000 | -57,756,000 | -54,402,000 | -42,982,000 | -44,247,000 | -50,118,000 | -34,525,000 | -40,179,000 | -29,080,000 | -25,040,000 | -24,664,000 | -19,284,000 | -18,680,000 | -19,451,000 | -16,089,000 | -15,767,000 | -15,343,000 | 30,313,000 | -55,961,000 | -2,387,000 | |
| yoy | -1.04% | -1.16% | 1.12% | 7.79% | 6.00% | 6.38% | -10.59% | 7.17% | 20.77% | 35.72% | 50.80% | 15.24% | 57.57% | 6.98% | 52.16% | 100.15% | 39.98% | 108.35% | 55.67% | 28.73% | 53.30% | 22.31% | 21.75% | -164.17% | -71.25% | 560.54% | |||||
| qoq | 12.37% | 1.67% | -9.58% | -4.20% | 12.23% | 4.01% | -3.62% | -5.79% | 12.63% | -12.57% | 15.53% | 6.17% | 26.57% | -2.86% | -11.71% | 45.16% | -14.07% | 38.17% | 16.13% | 1.52% | 27.90% | 3.23% | -3.96% | 20.90% | 2.04% | 2.76% | -150.62% | -154.17% | 2244.41% | ||
| net income margin % | |||||||||||||||||||||||||||||||
| net income per share | -0.62 | -0.56 | -0.62 | -0.71 | -0.74 | -0.66 | -0.62 | -0.75 | -0.82 | -0.73 | -0.89 | -0.87 | -0.83 | -0.67 | -0.68 | -0.79 | -0.55 | -0.65 | -0.53 | -0.45 | -0.45 | -0.38 | -0.38 | -0.43 | -0.4 | -0.4 | -0.42 | -0.963 | -2.48 | -0.15 | |
| weighted-average common shares outstanding - basic and diluted | 111,019,647 | 110,093,461 | 94,807,773 | 94,158,491 | 93,746,243 | 93,549,884 | 84,009,004 | 82,636,120 | 80,472,362 | 79,453,519 | 68,148,925 | 66,215,535 | 65,476,531 | 64,509,721 | 63,235,417 | 63,825,429 | 63,061,232 | 61,574,405 | 55,188,956 | 55,158,459 | 54,883,120 | 50,364,649 | 49,267,247 | 45,122,815 | 39,900,551 | 39,483,006 | 36,137,120 | ||||
| accretion of discount and amortization of premium on investments | 3,275,000 | 2,279,000 | 2,678,000 | 2,419,000 | |||||||||||||||||||||||||||
| research and development incentives | 500,000 | 500,000 | 250,000 | 186,000 | |||||||||||||||||||||||||||
| amortization of premium on investments - net | -282,000 | -156,000 | -396,000 | -577,000 | -527,750 | -744,000 | -727,000 | ||||||||||||||||||||||||
| interest and other income - net | 554,500 | 806,000 | 501,000 | ||||||||||||||||||||||||||||
| interest and other income net | 911,000 | 518,000 | 967,000 | 601,000 | |||||||||||||||||||||||||||
| (amortization of premium) accretion of discount on investments - net | -639,000 | -244,000 | |||||||||||||||||||||||||||||
| interest income | 459,000 | 473,000 | 288,000 | 786,000 | 33,000 | ||||||||||||||||||||||||||
| other income / (expense) net | -39,000 | ||||||||||||||||||||||||||||||
| other income / | -5,000 | ||||||||||||||||||||||||||||||
| other income | 15,000 | ||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -1,099,750 | -3,716,000 | |||||||||||||||||||||||||||||
| change in fair value of warrant liabilities | 66,750 | ||||||||||||||||||||||||||||||
| change in fair value of convertible bridge notes redemption rights derivative | 120,000 | ||||||||||||||||||||||||||||||
| change in fair value of 2020 convertible notes derivative liability | -10,698,250 | -46,649,000 | 1,859,000 | ||||||||||||||||||||||||||||
| weighted-average number of shares outstanding—basic and diluted | 22,573,195 | 16,327,003 | |||||||||||||||||||||||||||||
| cash flows from operating activities: | |||||||||||||||||||||||||||||||
| adjustments to reconcile net income to cash from operating activities: | |||||||||||||||||||||||||||||||
| noncash interest expense | 1,132 | 577 | |||||||||||||||||||||||||||||
| noncash rent expense | -5 | ||||||||||||||||||||||||||||||
| depreciation | 7 | 1 | |||||||||||||||||||||||||||||
| stock-based compensation | 1,932 | 1,558 | |||||||||||||||||||||||||||||
| changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||
| prepaid expenses and other assets | -968 | -574 | |||||||||||||||||||||||||||||
| accounts payable | 563 | -333 | |||||||||||||||||||||||||||||
| accrued expenses and other current liabilities | 487 | 651 | |||||||||||||||||||||||||||||
| net cash from operating activities | -10,377 | -6,050 | |||||||||||||||||||||||||||||
| cash flows from investing activities: | |||||||||||||||||||||||||||||||
| purchase of short-term investments | -29,117 | ||||||||||||||||||||||||||||||
| purchase of property and equipment | -318 | -30 | |||||||||||||||||||||||||||||
| net cash from investing activities | -29,435 | ||||||||||||||||||||||||||||||
| cash flows from financing activities: | |||||||||||||||||||||||||||||||
| proceeds from issuance of common stock in initial public offering, net of issuance costs | 38,085 | 38,115 | |||||||||||||||||||||||||||||
| proceeds from issuance of 2020 convertible notes in initial public offering | 21,000 | ||||||||||||||||||||||||||||||
| payments of 2020 convertible notes issuance costs | -1,841 | -1,841 | |||||||||||||||||||||||||||||
| proceeds from issuance of common stock in follow-on public offering, net of issuance costs | 73,955 | ||||||||||||||||||||||||||||||
| proceeds from exercise of stock options | 43 | ||||||||||||||||||||||||||||||
| principal payments on notes payable | -5,800 | -5,800 | |||||||||||||||||||||||||||||
| proceeds from exercise of warrants for series aa preferred stock | |||||||||||||||||||||||||||||||
| net cash from financing activities | 125,442 | ||||||||||||||||||||||||||||||
| net change in cash and cash equivalents | 85,630 | 45,394 | |||||||||||||||||||||||||||||
| cash and cash equivalents, beginning of period | 3,618 | 3,618 | |||||||||||||||||||||||||||||
| cash and cash equivalents, end of period | 89,248 | 49,012 | |||||||||||||||||||||||||||||
| supplemental disclosure of cash flow information: | |||||||||||||||||||||||||||||||
| cash paid for interest | 89 | 89 | |||||||||||||||||||||||||||||
| supplemental disclosure of noncash investing and financing activities: | |||||||||||||||||||||||||||||||
| accrual of series aa preferred stock dividends | |||||||||||||||||||||||||||||||
| acquisition of leasehold improvements | 445 | ||||||||||||||||||||||||||||||
| conversion of series aa preferred stock into common stock upon initial public offering | 46,383 | 46,383 | |||||||||||||||||||||||||||||
| conversion of series x preferred stock into common stock upon initial public offering | 548 | 548 | |||||||||||||||||||||||||||||
| conversion of convertible bridge notes into common stock upon initial public offering | 2,028 | 2,028 | |||||||||||||||||||||||||||||
| conversion of 2020 convertible notes into common stock | 66,375 | ||||||||||||||||||||||||||||||
| accretion of series aa preferred stock to redemption value | 130 | 130 | |||||||||||||||||||||||||||||
| reclassification of fair value of warrant liability to equity upon initial public offering | 215 | 215 | |||||||||||||||||||||||||||||
| reclassification of fair value of warrant liability related to exercise of preferred stock warrants | |||||||||||||||||||||||||||||||
| reclassification of deferred public offering costs to stockholders’ equity | 1,590 | 1,590 | |||||||||||||||||||||||||||||
| reclassification of deferred public offering costs to other assets | 256 | 256 | |||||||||||||||||||||||||||||
| retirement of treasury stock | |||||||||||||||||||||||||||||||
| net cash from investing activities: | -30 | ||||||||||||||||||||||||||||||
| proceeds from issuance of 2020 convertible notes in initial public offering, net of underwriting discounts | 21,000 | ||||||||||||||||||||||||||||||
| net cash from financing activities: | 51,474 |
We provide you with 20 years income statements for Rocket Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rocket Pharmaceuticals stock. Explore the full financial landscape of Rocket Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Rocket Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.